Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K
Emerging Adulthood01:27

Emerging Adulthood

663
Jeffrey Arnett's concept of emerging adulthood offers a framework to understand the unique developmental stage between adolescence and full-fledged adulthood, generally from ages 18 to 25. This period is marked by extensive exploration and shifts in identity, relationships, and career choices, a process known in psychology as role experimentation. Emerging adulthood reflects the evolving cultural expectations surrounding adulthood and the dynamic process of personal transformation during...
663
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

612
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
612
C4 Pathway and CAM01:27

C4 Pathway and CAM

49.1K
Most plants use the C3 pathway for carbon fixation. However, some plants, such as sugar cane, corn, and cacti that grow in hot conditions, use alternative pathways to fix carbon and conserve energy loss due to photorespiration. Photorespiration is the process that occurs when the oxygen concentration is high. Under such conditions, the rubisco enzyme in the Calvin cycle binds O2 instead of CO2, which halts photosynthesis and consumes energy.
C4 Pathway
The C4 pathway is used by plants such as...
49.1K
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

868
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
868
Introduction Cardiac Emergencies01:30

Introduction Cardiac Emergencies

327
Cardiac emergencies are critical situations involving the heart that require immediate medical intervention to prevent severe complications or death. These emergencies often arise from underlying heart conditions that impair the heart's ability to function correctly.Types of Cardiac EmergenciesThe most common types of cardiac emergencies include Acute Coronary Syndrome (ACS), myocardial infarction (MI), cardiac arrest, and heart failure.Acute Coronary Syndrome (ACS)Acute Coronary Syndrome (ACS)...
327

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute exacerbation in fibrotic interstitial lung disease: An International Working Group Report.

American journal of respiratory and critical care medicine·2026
Same author

Upper and lower airway crosstalk in acute exacerbations of COPD: a clinical and biological overview.

Expert review of respiratory medicine·2026
Same author

Opportunities for Human Lung Tissue-Based Studies in Fibrotic ILD Research.

American journal of respiratory and critical care medicine·2026
Same author

Bone involvement in sarcoidosis: Insights from a multicentre Italian cohort.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same author

How many blood eosinophil measurements are needed to identify COPD patients eligible for biologic therapy? A multi-source decision analysis simulation.

European journal of internal medicine·2026
Same author

Complete Right Upper Lobe Atelectasis Caused by an Endobronchial Hamartoma: Diagnostic Challenges and Successful Treatment With Rigid Bronchoscopy and Laser.

Respirology case reports·2026

Related Experiment Video

Updated: Jan 29, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

998

Most Promising Emerging Therapies for Pulmonary Fibrosis: Targeting Novel Pathways.

Lorenzo Carriera1,2, Roberto Lipsi2, Meridiana Dodaj2

  • 1Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.

Biomedicines
|January 28, 2026
PubMed
Summary

New antifibrotic therapies are emerging for interstitial lung diseases (ILDs), offering improved treatment options for patients with progressive lung fibrosis. A precision medicine approach is needed to tailor these novel treatments to individual patient phenotypes.

Keywords:
IPFPPFantifibrotic therapynerandomilastpulmonary fibrosis

More Related Videos

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

1.7K
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

911

Related Experiment Videos

Last Updated: Jan 29, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

998
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

1.7K
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

911

Area of Science:

  • Pulmonology
  • Pharmacology
  • Medical Research

Background:

  • Interstitial lung diseases (ILDs) are complex inflammatory and fibrotic lung disorders with limited treatment options.
  • Progressive phenotypes of ILDs, including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), require novel antifibrotic strategies.
  • Current guidelines highlight the need for therapies targeting fibrogenesis pathways.

Purpose of the Study:

  • To provide a comprehensive overview of emerging pharmacological agents for ILDs.
  • To analyze the mechanisms of action, efficacy, and safety of these novel therapies.
  • To discuss the transition towards a new generation of antifibrotic treatments and precision medicine.

Main Methods:

  • Review of recent preclinical and clinical studies on pharmacological agents for ILDs.
  • Analysis of data on mechanisms of action, efficacy, and safety profiles.
  • Synthesis of current guidelines and future therapeutic directions.

Main Results:

  • Nerandomilast has been recently approved, and several other agents are in Phase III trials.
  • These emerging therapies represent a significant advancement in controlling ILD progression.
  • The data suggest a potential for more effective disease management and improved patient outcomes.

Conclusions:

  • A new era of antifibrotic therapies for ILDs is dawning, with promising agents under investigation.
  • The development of novel drugs necessitates a precision medicine approach for phenotyped ILD patients.
  • Tailoring treatments to individual patient profiles is crucial for optimizing outcomes in ILDs.